Key facts
- This page summarizes John L. Slebir's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2026, 16:18.
John L. Slebir - 02 Nov 2026 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- SPRY
- Reported as of
- 02 Nov 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2026, 16:18:06 UTC
- Prior SEC filing
- 04 Nov 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathleen Scott, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
John L. Slebir filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 04 Nov 2026.
Change
- Previous filing in this sequence was filed on 04 Nov 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001475990
Primary reporting owner
Slebir John L
- Relationship
- Chief Legal Officer
- Address
- C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
- Signature
- /s/ Kathleen Scott, Attorney-in-Fact
- Signature date
- 04 Nov 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRY
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +1,199,482
- Change %
- Price
- $0.000000*
- Shares after
- 1,199,482
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,199,482
- Exercise price
- $3.05
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares subject to the option vest on October 26, 2027, and the remaining shares will vest monthly thereafter over three years.